Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Schizophrenia, Psychosis

Sygnature offers a range of assays that can be used to develop compounds to treat schizophrenia and related disorders. Compounds can be evaluated in well-established dopaminergic or hypoglutamatergic hyperactivity assays, as well as assessment in the conditioned avoidance assay; selective disruption of the conditioned response is a characteristic property of both typical and novel antipsychotic agents.

Amphetamine or PCP induced locomotor activity

  • Antipsychotic drugs reverse the hyperactivity induced by amphetamine or PCP in mice and rats

 

Reversal of PCP-induced hyperactivity in mice by the atypical antipsychotic olanzapine

 

Conditioned Avoidance Response

  • Typical and novel antipsychotic agents selectively inhibit the conditioned avoidance response in rats without affecting the unconditioned response. The efficacy of a drug to suppress conditioned avoidance responding in rats correlates with its ability to reduce psychosis in man. The conditioned avoidance response test is a crucial model in development of drugs to treat schizophrenia

 

The atypical antipsychotic Olanzapine reduces conditioned avoidance responding in rats

 

DOI-induced head twitch in mice

  • Many novel antipsychotic agents inhibit DOI-induced head twitch indicating an interaction with the serotonergic system

 

Inhibition of DOI-induced head twitch in mice by the atypical antipsychotic olanzapine

 

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.